There's a new precaution section for Gleevec


The occasional occurrence of severe congestive heart failure and left ventricular dysfunction with use of imatinib (Gleevec) has prompted manufacturer Novartis to revise the Precautions section of the prescribing information. According to the company, most patients experiencing cardiac events had other comorbidities and risk factors, including a prior medical history of cardiac disease and advanced age. At-risk patients should be monitored carefully, and any patients with signs or symptoms consistent with cardiac failure should be evaluated and treated.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.